Genetics - Publications - Faculty & Research

01 Oct 2001
News

Philip L. Yeo: The Next Big Thing

sciences and bioengineering. "In the next generation, we will know the genetic and molecular mechanisms of disease," Yeo declares. "Biomedical science will control and eradicate cancer and AIDS, and individualized medicine will be the... View Details

Keywords: Government

12 Nov 2015
Research & Ideas

Can Consumers be Trusted with Their Own Health Care?

reveals a person’s genetically based health risk across dozens of disease categories. 23andMe test results showed one patient at higher risk of liver and bowel cancer—and that made sense, given family history. The patient discussed the... View Details

Keywords: by Dina Gerdeman; Health

05 Dec 2013
Op-Ed

Encourage Breakthrough Health Care by Competing on Products Rather Than Patents

Like many people interested in the tangled connections between health care progress and intellectual property rights, I avidly followed the Myriad Genetics case, decided by the Supreme Court this June 13. In sum, molecular diagnostics... View Details

Keywords: by Richard G. Hamermesh; Biotechnology; Health

14 Jul 2009
First Look

First Look: July 14

Course MaterialsThe DiagnoFirst Opportunity Harvard Business School Case 309-112 John Mason, a principle at Oldwell Partners, was facing a decision of whether or not to invest in DiagnoFirst, a molecular diagnostics firm. DiagnoFirst's key product was a View Details

Keywords: Martha Lagace

03 Mar 2015
First Look

First Look: March 3

a lower price but charge more for the cartridges necessary to run a sample and earn its primary revenue from these cartridges. The third model would see GenapSys sell its device at or around cost, but use the data customers generated to create a proprietary database of... View Details

Keywords: Sean Silverthorne

October 2011
Case

Gene Sequencing: Staking a Position in an Expanding Industry

By: Richard G. Hamermesh, Mara Aspinall and Phillip Andrews

Towards the end of 2010, companies in the gene sequencing industry were pushing aggressive R&D programs to develop technologies and products in the race to sequence the entire human genome at a cost of $1,000. It remained to be seen when the "$1,000 genome" would... View Details

Keywords: Genetics; Business Growth and Maturation; Business Plan; Competition; Venture Capital; Biotechnology Industry

Citation

Find at Harvard

01 Mar 2012
News

How to Close the Health Gap

questions are finally focusing on the health-care needs of the poor. Some teams, for example, are working on genetic modifications that would render the mosquito unable to transfer malaria. Those developments make Daar and Singer... View Details

Keywords: Sean Silverthorne; Ambulatory Health Care Services; Health, Social Assistance; Publishing Industries (except Internet); Information

27 Feb 2024
Blog Post

Fighting Cancer with a Novel Cell Therapy: Ananya Zutshi (MS/MBA '21)

Ananya Zutshi (MS/MBA 2021) wanted a career in pharmacology biotech, but wasn’t sure if she wanted to be on the management side or scientific side. She studied biomedical engineering as an undergraduate at Duke University, where she participated in View Details

October 2001 (Revised March 2008)
Case

Anagene, Inc.

By: Robert S. Kaplan and Christina L. Darwall

An entrepreneurial, publicly traded biotech company has begun production and sales of its core product--cartridges that permit DNA samples to be analyzed on a microchip. In the early quarters, sales are difficult to forecast and the company has experienced fluctuating... View Details

Keywords: Cost Accounting; Financial Reporting; Production; Performance Capacity; Risk and Uncertainty; Genetics; Governing and Advisory Boards; Biotechnology Industry; California

Citation

Educators

Purchase

15 Dec 2015
News

The Year in Ideas 2015

qualities, achieved through the controversial technology of genetic modification. Genetically modified foods, also known as GMOs, are a confusing topic for consumers. In the United States, 95 percent of the... View Details

Keywords: Julia Hanna, Christine Lejeune, Dan Morrell, and April White

01 Dec 2013
News

To Market, to Market

following technologies: Miniproteins that can penetrate cells and act on targets that were previously considered "undruggable." The application of unique genetic and biochemical methods to develop new antibiotics targeting the outer... View Details

Keywords: Scientific Research and Development Services

01 Jun 2000
News

Managing the Map

Health (NIH) undertook the Human Genome Project, an effort to map the extraordinarily intricate chemical composition of the human genome. Scientists have long believed that understanding the vast genetic code underlying all human life... View Details

Keywords: Peter K. Jacobs

22 Sep 2021
Blog Post

Student Spotlight: Jesse Lou (MBA 2022) – Working to Change the Food System

oils, using a lot less land and resources. It’s no secret that these are powerful organisms, but past attempts to scale production have faced challenging unit economics (high up-front capital costs for facilities, selling into commodity markets). We believe that... View Details

11 Jun 2021
News

The Power of Resilience

what my priorities are. I actually didn't know what that mission-driven work would be at the time. But I came across a company whose mission it was to democratize access to genetic testing for hereditary cancers. It was that power of... View Details

04 Nov 2021
Blog Post

STUDENT SPOTLIGHT: JESSE LOU (MBA 2022) – WORKING TO CHANGE THE FOOD SYSTEM

oils, using a lot less land and resources. It’s no secret that these are powerful organisms, but past attempts to scale production have faced challenging unit economics (high up-front capital costs for facilities, selling into commodity markets). We believe that... View Details

Keywords: Technology; Entrepreneurship

04 Nov 2021
Blog Post

STUDENT SPOTLIGHT: JESSE LOU (MBA 2022) – WORKING TO CHANGE THE FOOD SYSTEM

oils, using a lot less land and resources. It’s no secret that these are powerful organisms, but past attempts to scale production have faced challenging unit economics (high up-front capital costs for facilities, selling into commodity markets). We believe that... View Details

October 2010 (Revised November 2010)
Background Note

Plavix: Drugs in the Age of Personalized Medicine

By: Richard G. Hamermesh, Mara G. Aspinall and Rachel Gordon

PIavix, one of the world's best selling drugs in 2010, appears to have a limited future. Its patent was due to expire soon, and recently new data had been discovered that indicated that a small subset of the population would be at risk for stroke, heart attack, or even... View Details

Keywords: Health Care and Treatment; Product Positioning; Business and Government Relations; Genetics; Competitive Strategy; Pharmaceutical Industry

Citation

Educators

Purchase

Web

Winners & Success Stories | New Venture Competition

Panjiva) will help smaller businesses find overseas suppliers they can trust; unlike existing supplier databases, GRC’s “reputation database” will feature feedback from previous customers about what it’s like to do business with the suppliers in our database. Good... View Details

November 2009 (Revised March 2010)
Case

Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story

By: Richard G. Hamermesh, Raju Kucherlapati and Rachel Gordon

In May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, developed to fight metastatic colorectal cancer, had been rejected. This was especially surprising news given that a similar rival drug had... View Details

Keywords: Entrepreneurship; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Marketing Strategy; Product Positioning; Genetics; Biotechnology Industry; Europe; United States

Citation

Educators

Purchase